TherapeuticsMD (TXMD) 10-K2021 FY Annual report

Filed: 23 Mar 22, 4:54pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: anniversary, ATM, bid, Black, broker, carryback, CEO, chance, chromosome, cliff, conclusion, contended, CRL, currency, deadline, deficiency, dollar, drove, earliest, Earnout, ERB, EVP, exit, explanatory, figure, GoodRx, hearing, hereto, Hugh, hypothetical, ID, Instruction, intermittent, issuable, lessee, lessor, Marlan, meantime, molecule, monetize, motion, multifactorial, nonfinancial, nonqualified, pace, Panel, parent, pathway, pharmacodynamic, pharmacokinetic, PIK, placement, practitioner, premature, prespecified, promptly, proof, regain, regained, residual, resigned, RSU, seal, sex, speed, split, tactical, thousand, TM, transportation, turnover, unamortized, unbilled, unrounded, unsecured, unsettled, variant, variation, vitaCareTM, waivable, waived, waiver, Walker, weighed, welfare, York

Removed: accumulation, acknowledge, allocable, allocate, allocated, annum, ASC, assessing, attractive, automatic, Bayer, body, broader, calculating, Carroll, carryover, categorize, categorized, ceased, Certified, climate, communicate, compare, comparison, concurrently, consolidation, construction, consumed, converted, Cooperation, corroboration, coupled, coupon, decade, depicting, determinable, discounted, disposed, divided, easily, electronically, entitle, EPS, estimating, excellent, exchanged, FASB, Finizio, gas, GBI, gluten, GMP, Goldman, graph, greatly, grouped, growing, Institute, intelligence, intention, interpretation, introducing, invested, invoice, JoAnn, kosher, Kyleena, leader, Linkbase, Lupin, membership, methodology, minimize, Mining, Morgan, Mylan, necessarily, noteholder, NYSE, observation, OCs, OPERA, OTCQB, overnight, owing, paper, par, PCT, peer, physical, Pillpack, Pinkerton, practicable, pro, profile, rata, ratably, recognizing, recoverability, recruitment, redomicile, reinvestment, REPLENISH, representative, requisite, Schema, Secretary, shell, simplified, Skyla, spite, streamline, sugar, targeting, Task, taxing, Taxonomy, therapeutic, trajectory, Treaty, trimester, unconditional, undiscounted, unfunded, Utah, vegan, viii, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated TXMD transcripts

TXMD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER

In connection with the Annual Report on Form 10-K of TherapeuticsMD, Inc. (the “Company”) for the year ended December 31, 2021 (the “10-K Report”), as filed with the Securities and Exchange Commission on the date hereof, I, James C. D’Arecca, Chief Financial Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The 10-K Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

(2)

The information contained in the 10-K Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 23, 2022

/s/ James C. D’Arecca

James C. D’Arecca

Chief Financial Officer

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.